Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
Other Sizes |
|
Targets |
Apoptosis
|
---|---|
ln Vitro |
Treatment of L929 cells with periplocin (5–20 μM) for 48 hours resulted in a 131% increase in proliferation [1]. Periplocin dose-diagnoses and time-promotes fibroblast migration [1]. Periplocin (5 – 20 μM; 30-120 minutes; L929 cells) significantly promotes fibroblast migration. L929 is increased by periplocin (5–20 μM; 48 hours) Periplocin induces PI3K/Akt and Src/ERK activation via Na/KATPase [1].
|
ln Vivo |
Hepatocellular carcinoma (HCC) growth is inhibited in a mouse xenograft tumor model by Periplocin (5–20 mg/kg; intraperitoneal injection; daily; for 14 days; female SCID mice) treatment [2].
|
Cell Assay |
Cell Viability Assay[1]
Cell Types: L929 cells Tested Concentrations: 5 μM, 10 μM, 20 μM Incubation Duration: 48 hrs (hours) Experimental Results: Proliferation increased up to 131% at 20 μM. Western Blot Analysis[1] Cell Types: L929 Cell Tested Concentrations: 5 μM, 10 μM, 20 μM Incubation Duration: 30 minutes, 60 minutes, 120 minutes Experimental Results: Src, ERK, PI3K and Akt phosphorylation of the active site were dose-dependent Sex increases in a time-dependent manner. |
Animal Protocol |
Animal/Disease Models: Female SCID (severe combined immunodeficient) mouse (6-8 weeks old) injected with Huh-7 cells [2]
Doses: 5 mg/kg, 20 mg/kg Route of Administration: intraperitoneal (ip) injection; daily; continued for 14 days Experimental Results: Inhibition Growth of hepatocellular carcinoma (HCC) in mouse xenograft tumor models. |
References |
[1]. Chen L, et al. Periplocin promotes wound healing through the activation of Src/ERK and PI3K/Akt pathways mediated by Na/K-ATPase. Phytomedicine. 2019 Apr;57:72-83.
[2]. Cheng CF, et al. Antitumor Effect of Periplocin in TRAIL-Resistant Human Hepatocellular Carcinoma Cells through Downregulation of IAPs. Evid Based Complement Alternat Med. 2013;2013:958025. |
Molecular Formula |
C36H56O13
|
---|---|
Molecular Weight |
696.82
|
Exact Mass |
696.37209184
|
CAS # |
13137-64-9
|
Appearance |
White to off-white solid
|
SMILES |
C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2CC[C@@]3([C@H]4CC[C@@]5([C@H](CC[C@@]5([C@@H]4CC[C@@]3(C2)O)O)C6=CC(=O)OC6)C)C)OC)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO)O)O)O
|
InChi Key |
KWBPKUMWVXUSCA-AXQDKOMKSA-N
|
InChi Code |
InChI=1S/C36H56O13/c1-18-31(49-32-30(41)29(40)28(39)25(16-37)48-32)24(44-4)14-27(46-18)47-20-5-9-33(2)22-6-10-34(3)21(19-13-26(38)45-17-19)8-12-36(34,43)23(22)7-11-35(33,42)15-20/h13,18,20-25,27-32,37,39-43H,5-12,14-17H2,1-4H3/t18-,20+,21-,22+,23-,24+,25-,27+,28-,29+,30-,31-,32+,33-,34-,35+,36+/m1/s1
|
Chemical Name |
3-[(3S,5S,8R,9S,10R,13R,14S,17R)-5,14-dihydroxy-3-[(2R,4S,5R,6R)-4-methoxy-6-methyl-5-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-10,13-dimethyl-2,3,4,6,7,8,9,11,12,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]-2H-furan-5-one
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO : ~100 mg/mL (~143.51 mM)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (3.59 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (3.59 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (3.59 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 1.4351 mL | 7.1755 mL | 14.3509 mL | |
5 mM | 0.2870 mL | 1.4351 mL | 2.8702 mL | |
10 mM | 0.1435 mL | 0.7175 mL | 1.4351 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.